New vaccine aims to shield sickle cell kids from deadly infections

NCT ID NCT07247188

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jan 05, 2026 · Last updated May 19, 2026 · Updated 23 times

Summary

This study tests a new 21-valent pneumococcal vaccine (PCV21) in 100 children aged 2 to 17 with sickle cell disease, who are at high risk for serious infections. Researchers will compare PCV21 to a licensed vaccine to see if it is safe and helps the body produce protective antibodies. The goal is to find a better way to prevent pneumonia and other infections in these vulnerable children.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Site # 2140001
RECRUITING

Santo Domingo, Dominican Republic
Site # 2140003
RECRUITING

Santo Domingo, Dominican Republic
Site # 8400001
RECRUITING

New Brunswick, New Jersey, 08901, United States
Site # 8400002
RECRUITING

Atlanta, Georgia, 30322, United States
Site # 8400003
RECRUITING

Omaha, Nebraska, 68114, United States
Site # 8400004
RECRUITING

Houston, Texas, 77030, United States
Site # 8400006
RECRUITING

Atlanta, Georgia, 30310, United States

Conditions

Explore the condition pages connected to this study.

SICKLE CELL DISEASE